1,401 Shares in Cencora, Inc. (NYSE:COR) Bought by Fermata Advisors LLC

Fermata Advisors LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,401 shares of the company’s stock, valued at approximately $315,000.

A number of other institutional investors also recently bought and sold shares of COR. Concord Wealth Partners purchased a new stake in Cencora during the 3rd quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora in the second quarter valued at approximately $36,000. Ashton Thomas Securities LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $41,000. Fairscale Capital LLC acquired a new stake in shares of Cencora during the second quarter worth $54,000. Finally, Modus Advisors LLC purchased a new position in Cencora in the 4th quarter valued at $54,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,696 shares of company stock worth $22,862,734. Insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of a number of analyst reports. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Evercore ISI lifted their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company cut their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Finally, Barclays lifted their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Stock Up 0.5 %

Cencora stock opened at $242.11 on Friday. The firm has a market capitalization of $46.80 billion, a price-to-earnings ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The stock’s fifty day moving average is $237.52 and its two-hundred day moving average is $233.85.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.